Pancreatic cysts are commonly seen with increasing use of cross-sectional imaging. They range from a benign inflammatory process that can produce pseudocysts to malignant lesions such as mucinous cystadenocarcinoma. Other common pancreatic cystic lesions include intraductal papillary mucinous neoplasms and serous cystadenomas. Optimized imaging protocols dedicated to imaging the pancreas are required, such as multiphasic computed tomography, magnetic resonance imaging/magnetic resonance cholangiopancreatography, or endoscopic ultrasound, to fully detect and characterize the lesions. A confident diagnosis can be made on imaging when features such as calcifications, pancreatic duct diameter, main duct communication, and mural nodules are assessed. Additionally, pathologic evaluation from fluid/tissue sampling aids in diagnosis. Optimal management of pancreatic cysts is achieved based on the imaging features, conveying key findings in the radiology report, pathologic evaluation, and clinical factors.

The American College of Radiology (ACR) is attempting to simplify concepts as well as help in the management of pancreatic cystic lesions according to size, patient age, and risk stratification by imaging.¹

### Imaging Evaluation

Pancreatic cysts are often incidental findings on CT performed for various other reasons. Further evaluation with an appropriate CT or MRI protocol are often necessary for optimal characterization; which typically consists of a dedicated pancreatic protocol multiphasic CT, MRI/magnetic resonance cholangiopancreatography (MRCP), or endoscopic ultrasound (EUS). A dedicated CT study with pancreatic protocol consists of a typically precontrast component and effective late arterial and porta venous phases obtained approximately 40 to 50 seconds and 70 to 80 seconds, respectively, after contrast injection.² This is the typical pancreatic phase (late arterial phase), unlike the early arterial phase which obtain images around 30 seconds after contrast injection.³ The late arterial phase provides optimal differentiation between normal pancreatic parenchymal and hypodense lesions.
and provides good opacification of the arterial and venous vessels. MRI has been shown to be better than CT in differentiating IPMN from other cystic pancreatic lesions (96.8 vs. 80.6% sensitivity and 90.8 vs. 86.4% specificity). Furthermore, consideration should be made to obtain MRI of the abdomen for the younger population, since the ACR algorithm requires follow-up exams for up to 10 years with different intervals depending on age and lesion size. T2-weighted imaging using breath hold fast spin echo (FSE) or free breathing single shot fast spin echo (SSFSE) techniques are important in axial and coronal planes for better assessment. The use of contrast is also recommended.

Additionally, optimal imaging often consists of thin-section imaging and appropriate postprocessing techniques, which is especially needed in determining whether there is cystic communication with the pancreatic duct. Multiplanar reformattting (MPR) and curved MPR (cMPR), alone or in combination with oblique axial images, are superior to axial images when evaluating the pancreatic duct as shown by some studies. Also, another postprocessing technique is minimal intensity projection (MinIP), which may enhance the detection of cystic lesions, their internal characteristics and communication with the pancreatic ducts if any is present. Conveying key features identified on imaging via the radiology report is crucial for patient management. Therefore, the ACR encourages reporting worrisome features and high-risk stigmata, as well as any change such as interval growth, as listed in Tables 1 and 2. Growth of lesions remain the most widely use parameter for surveillance (Table 3).

Pathologic Evaluation

Since all cystic lesions in the pancreas are presumed mucinous unless definite history of pancreatitis or previous biopsy was performed, fluid/tissue sampling is considered when CT or MRI features are worrisome or nonspecific.

The goal is to obtain a 2-cc sample submitted for a panel of basic laboratories and staining (Table 4). The lesion must be at least 1.7 to 2 cm in maximum dimension and the yield dependent on the endoscopic expertise of the gastroenterologist. Combined with optimal imaging, the sensitivity and specificity of diagnosis ranges between 90 to 100% and 92 to 98%, respectively.

Pseudocysts

The most common cystic pancreatic lesion has reportedly been a pseudocyst (up to 80%), therefore the presence of previous inflammatory history is highly relevant.

Pseudocysts develop after approximately 4 weeks from a single- or multiple-acute episode of edematous pancreatitis. They are homogeneous in density and well circumscribed and need to be differentiated from wall off necrosis (WON), which can develop after necrotizing pancreatitis (Fig. 1). The latter is usually more inhomogeneous and higher in density due to necrotic tissue or blood products.

Chronic pancreatitis can display imaging features overlapping with those of main duct IPMN, as both can present with main pancreatic ductal dilatation and parenchymal atrophy. Nevertheless, imaging features favoring chronic pancreatitis include ductal and parenchymal stones and lack of enhancing mural nodules or a bulging papilla.

Again, the increasing use of thinner cross-sectional imaging is revealing cystic pancreatic lesions other than pseudocysts, such as IPMN, mucinous cystic neoplasm (MCN), or serous cystadenoma.

Table 1  Worrisome features of cystic pancreatic lesions

<table>
<thead>
<tr>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion &gt; 3 cm</td>
</tr>
<tr>
<td>Thickened wall</td>
</tr>
<tr>
<td>Nonenhancing mural nodule</td>
</tr>
<tr>
<td>Main pancreatic duct &gt; 7 mm</td>
</tr>
</tbody>
</table>

Table 2  High-risk stigmata of cystic pancreatic lesions

<table>
<thead>
<tr>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhancing mural nodule</td>
</tr>
<tr>
<td>Main pancreatic duct &gt; 10 mm</td>
</tr>
<tr>
<td>Clinical obstructive jaundice</td>
</tr>
</tbody>
</table>

Table 3  Growth of lesions surveillance

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Increase in Long Axis Diameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion &lt; 0.5 cm</td>
<td>100%</td>
</tr>
<tr>
<td>Lesion 0.5–1.5 cm</td>
<td>50%</td>
</tr>
<tr>
<td>Lesion &gt; 1.5 cm</td>
<td>20%</td>
</tr>
</tbody>
</table>

Fig. 1  CT demonstrates pseudocyst (white arrow) in patient with history of chronic pancreatitis, pathology confirmed. CT, computed tomography.
Intraductal Pancreatic Mucinous Neoplasm
The most common resected cystic lesions of the pancreas are IPMNs, accounting for approximately 50% of cases. They are more prevalent in men and typically occur in the sixth or seventh decade. These tumors can originate from the main pancreatic duct or its side branch; being classified as main duct, side branch, or combined tumors. The side branch is the most common variant. They can present histologically from benign dysplasia, borderline malignancy, to infiltrative carcinomas. Features seen on CT described as predictive of increased malignant risks include main pancreatic ductal dilatation greater than 10 mm, diffuse or multifocal involvement, calcified intraluminal content, bulging papilla, and solid contrast enhancing papillary proliferations. Main duct forms of IMPN are at a higher incidence of malignant transformation than side branch varieties, 38 to 68% vs. 12 to 47%. However, side branch IPMN measuring larger than 3 cm or growth of greater than 2 mm/year is associated with increased malignancy risks as shown by some studies. Those lesions without the characteristics of increased malignant risks show a trend toward observation as described in different guidelines, such as from the ACR or publications by Tanaka et al. As stated previously, chronic pancreatitis can have imaging features that overlap with those of main duct IPMN, as both can present with main pancreatic ductal dilatation and parenchymal atrophy. Nevertheless, imaging features again favoring chronic pancreatitis include ductal stones and lack of enhancing ductal wall nodules or a bulging papilla.

It is important to identify the communication of the cystic neoplasm to the main pancreatic duct to secure the diagnosis of a side branch or side duct IPMN. If no communication is visualized in a well-performed study, MCN is more likely and accounts for approximately 25% of all cystic resected lesions.

Mucinous Cystic Neoplasm
MCN of the pancreas are typically referred as “mother cysts” as they occur in women in the fourth to fifth decade. Unlike serous cystadenoma, its histology ranges from a benign adenoma and borderline tumor to noninvasive and invasive carcinoma. They present as either a unilocular or multilocular macrocystic lesion as seen on CT. Imaging characteristics concerning for malignant potential include the presence of a thick enhancing septate, solid mural papillary projections, or partially solid component. The cyst

---

Fig. 2 Multicystic lesion with communication to MPD (white arrow) compatible with side branch IPMN on MRI, confirmed on cytology. IPMN, intraductal pancreatic mucinous neoplasms; MPD, main pancreatic duct; MRI, magnetic resonance imaging.

Fig. 3 Typical appearance of a side branch IPMN on CT with MPD communication (white arrow), confirmed on cytology. CT, computed tomography; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct.
may have wall calcifications, which distinguishes these lesions from the centrally calcified serous cystadenomas (►Fig. 4). As stated before, a lack of communication with the main pancreatic duct or side branch helps differentiate these cysts from an IPMN.

**Serous Cystadenoma**

Serous cystadenoma of the pancreas is generally benign and has been referred as “grandmother cysts” as they commonly affect women in the sixth to seventh decade. On CT imaging, they are comprised of small multiple typically greater than six cysts, each less than 2 cm in diameter and do not communicate with the pancreatic duct. When larger, serous cystadenomas are seen as sponge-like mass (microcystic) with a central punctate or globular calcification (►Fig. 5). They can also present as a unilocular mass rarely, which can be indistinguishable from a mucinous cystadenoma or cystadenocarcinoma. Further evaluation with EUS with biopsy may be of benefit.

**Other Features**

Additionally, there are other imaging features that can aid in charactering cystic pancreatic lesions. Measuring cyst density (Hounsfield’s unit [HU]), is an example; as reported by Chalian et al, cysts with attenuation greater than 14.5 HU are more associated with pseudocysts than unilocular mucin-containing cysts (accuracy of 73.5%).

Benign pancreatic cysts also more commonly exhibit a lobulated shape, thin wall and smooth internal surface; in contrast to premalignant and malignant lesions demonstrating often a round, oval, or complex shape with thick wall, and irregular internal surface. As previously described, EUS-guided cyst fluid aspiration can further help to characterize pancreatic cysts; mucinous tumors will often yield elevated levels of carcinoembryonic antigen (CEA), or carbohydrate antigen 19 to 9 (CA19–9) and increased fluid viscosity.

**Management**

Management of cystic pancreatic lesions depends on optimal imaging and characterization (►Fig. 6). A cystic lesion characteristic of serous cystadenoma is not surgically resected unless 4 cm or more in size and symptomatic. On the contrary, imaging features suggestive of MCN are resected in suitable candidates, regardless of size secondary to their malignant potential. IPMN tumors less than 3 cm in size and simple in appearance can be followed according to the 2012 international consensus guidelines from the International Association of Pancreatology in Fukuoka, Japan; a 2- to 3-year follow-up for lesions less than 10 mm, yearly for lesions 10 to 20 mm, and 3 to 6 months for lesions 20 to 30 mm.

**Conclusion**

Pancreatic cysts are now commonly seen with increasing use of cross-sectional imaging. They range from a benign inflammatory process that can produce pseudocysts to malignant lesions such as mucinous cystadenocarcinoma. Optimized imaging protocol dedicated to imaging the pancreas is required, such as multiphasic CT, MRI/MRCP, or EUS to fully detect and characterize the lesions. A confident diagnosis can be made on imaging when features such as calcifications, pancreatic duct diameter, main duct communication, and mural nodules are assessed. Additionally, pathologic evaluation from fluid/tissue sampling aid in diagnosis. Optimal management of pancreatic cysts is achieved based on the imaging features, pathologic evaluation, and clinical factors.
Fig. 6 Flow chart of pancreatic cysts for diagnosis and management. IPMN, intraductal pancreatic mucinous neoplasms; MCN, mucinous cystic neoplasm.

Conflict of Interest
None declared.

Acknowledgments
The authors wish to acknowledge Raghu Vikram, MD, for his support of this work.

References